STAT+: With data on a cancer drug derived from red blood cells looming, Rubius Therapeutics seeks to shed its bumbling image

Rubius Therapeutics is the can’t-do-anything-right biotech spinout from the high-profile venture capital firm Flagship Pioneering. Moderna — Flagship’s runaway success story — it is not.

But an opportunity for Rubius to improve its bumbling reputation — and continue a recent recovery in its stock price — looms. The company is preparing to disclose the first clinical data from an effort to transform red blood cells into cancer-fighting drugs.

Continue to STAT+ to read the full story…

STAT+: With data on a cancer drug derived from red blood cells looming, Rubius Therapeutics seeks to shed its bumbling image

Leave a Reply

Your email address will not be published. Required fields are marked *

Scroll to top